Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients With Relapsed/Refractory Thrombotic Thrombocytopenic Purpura (TTP) - Hemolytic Uremic Syndrome (HUS)

NCT00531089 is registered in ClinicalTrials.gov with Hamilton Health Sciences Corporation as lead sponsor.

NCT NCT00531089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00531089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients With Relapsed/Refractory Thrombotic Thrombocytopenic Purpura (TTP) - Hemolytic Uremic Syndrome (HUS)
Lead sponsor
Hamilton Health Sciences Corporation
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2007
Completion date
January 31, 2011
Enrollment
60 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hemolytic uremic syndrome, thrombotic thrombocytopenic purpura